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ABSTRACT
MicroRNAs (miRNAs) have recently been proposed
as a versatile class of molecules involved in regu-
lation of a variety of biological processes. However,
the role of miRNAs in TGF-b-regulated biological
processes is poorly addressed. In this study, we
found that miR-24 was upregulated during myoblast
differentiation and could be inhibited by TGF-b1.
Using both a reporter assay and Northern blot
analysis, we showed that TGF-b1 repressed
miR-24 transcription which was dependent on the
presence of Smad3 and a Smads binding site in the
promoter region of miR-24. TGF-b1 was unable to
inhibit miR-24 expression in Smad3-deficient myo-
blasts, which exhibited accelerated myogenesis.
Knockdown of miR-24 led to reduced expression
of myogenic differentiation markers in C2C12 cells,
while ectopic expression of miR-24 enhanced
differentiation, and partially rescued inhibited myo-
genesis by TGF-b1. This is the first study demon-
strating a critical role for miRNAs in modulating
TGF-b-dependent inhibition of myogenesis, and
provides a novel mechanism of the genetic regula-
tion of TGF-b signaling during skeletal muscle
differentiation.
INTRODUCTION
The development of skeletal muscle (myogenesis) is a
highly regulated, multi-step process in which pluripotent
mesodermal cells give rise to myoblasts that subsequently
withdraw from the cell cycle and diﬀerentiate into
myotubes (1,2). Myogenesis is orchestrated by the basic
helix-loop-helix myogenic regulatory factors (MRFs),
Myf5, MyoD, Myogenin and MRF4. These factors
control myoblast commitment and diﬀerentiation via
regulating the gene transcription by binding to sequence-
speciﬁc DNA elements (E box, CANNTG) in the
promoters of muscle genes (3,4). Activation of muscle
gene expression by MRFs is also dependent on their
association with other molecules such as members of the
MEF2 family of transcription factors, MEF2A-D (5,6).
Several studies have shown that myogenesis is also
regulated by a number of growth factors, including
ﬁbroblast growth factor, insulin-like growth factor and
transforming growth factor-b (TGF-b) (7–9).
TGF-b signaling, an important and complex signaling
pathway, controls a diverse set of cellular processes
(10,11). TGF-b signaling is transmitted from cell surface
to nucleus by Smad proteins (12), of which there are three
functional classes. The receptor-regulated Smads, Smad2
and 3, transduce signals from TGF-bs and Activins, while
Smads 1, 5 and 8 mediate BMP signaling pathways. As the
common mediator, Smad4 complexes with receptor-
regulated Smads to transcribe target genes in response
to either BMPs or TGF-b/Activin signals. Finally, the
inhibitory Smads, Smad6 and Smad7, are negative
regulators of TGF-b signaling (12).
Members of TGF-b have been shown to potently inhibit
terminal diﬀerentiation of cultured myoblasts by down-
regulating MRFs (13–16). Myostatin, a member of the
TGF-b family, has been shown to be a negative regulator
of muscle diﬀerentiation and growth (17,18). Recent
studies revealed that Smad3 mediates the suppression of
myogenesis by TGF-b through suppressing the expression
of E-box muscle genes and MEF2 proteins (19,20), while
Smad7 has been implicated in promoting and enhancing
myogenesis by interacting with MyoD and abrogating of
Myostatin signaling (21).
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single-stranded RNAs that silence gene expression by
translational repression and degradation of cognate
mRNAs by binding to the 30 untranslated region of
target mRNAs (22–24). Accumulating evidence supports
a role for miRNAs in the regulation of myogenesis (25).
miR-1/-206 and miR-133 play opposing roles in modulat-
ing skeletal muscle proliferation and diﬀerentiation. While
miR-1 and miR-206 promote myogenesis, miR-133 inhibits
myoblast diﬀerentiation and promotes proliferation by
repressing serum response factor and a key splicing factor
(26–29). miR-181 has been shown to promote myoblast
diﬀerentiation by downregulating a myogenic inhibitor,
the homeobox protein Hox-A11 (30).
Recently, several reports have implicated miRNAs in
TGF-b signaling. miR-192 was found to be increased by
TGF-b in mouse mesangial cells, and play an important
role in the kidney and diabetic nephropathy in controlling
TGF-b-induced Col1a2 expression by downregulating
Smad-interacting protein 1 (31). Zebraﬁsh miR-430 was
found to be able to dampen and balance the expression of
the Nodal agonist squint and the TGF-b Nodal antagonist
lefty (32). Xenopus laevis miR-15 and miR-16 could restrict
the size of the organizer by targeting the Nodal type II
receptor Acvr2a (33). However, the miRNA which
functions in TGF-b-inhibited myogenesis has not been
reported.
In this work, we identiﬁed miR-24 as a miRNA that
involved in the inhibition of skeletal muscle diﬀerentiation
by TGF-b, thus revealing a new level of regulation in
TGF-b signaling-regulated myogenesis.
MATERIALS AND METHODS
Mousestrains
To obtain mice with targeted deletion of Smad4 gene
in heart, homozygous mice for the ﬂoxed Smad4 allele
(Smad4
Co/Co) (34) were bred with aMHC-Cre transgenic
mice in which the expression of Cre recombinase is driven
by a-MHC promoter (35). The genotyping was performed
as described (35). The generation and genotyping of
Smad3
ex8/ex8 null mice, in which the 8th exon of Smad3
gene is completely deleted by homologous recombination,
were described previously (36).
Vector construction
For the expression of miR-24, genomic fragment of mouse
miR-24 precursor was ampliﬁed by PCR using the primer
pairs: 50-GACCCCATCTCCTCAGGCC-30 and 50-CAGC
TGTTTGGACACCCAGATG-30. The PCR product was
ﬁrst cloned into pIRES2-EGFP (Invitrogen, Carlsbad,
CA, USA). The fragment containing CMV promoter and
miR-24-2 precursor was then cloned into pINCO retroviral
vector (37) to generate pINCO-miR24.
For promoter assay, 1040-bp genomic fragment
upstream of the transcriptional start site of miR-24-2
precursor was ampliﬁed by PCR using the primer pairs:
50-CCCTGGTACGGGTGCTAAATAC-30 and 50-AGG
CACAGTGAGGGGGGCA-30. To mutate potential
Smads-binding site in the promoter region, an overlapping
PCR was performed with two additional primers
(50-AAGGATCCACACCCTAGCCCTC-30,5 0-AAGGA
TCCTTTTGCTGAGTTTAGATTCTGTCCCCA-30)i n
addition to above primers. The PCR product was cloned
into pGL3-basic (Promega, Madison, WI, USA) to
generate pGL3-P24 and pGL3-P24-mut.
For the evaluation of ectopic expressed miR-24,a
synthesized linker (50-GATCTCTGTTCCTGCTGAACT
GAGCCAA-30 and 50-CGCGTTGGCTCAGTTCAGC
AGGAACAGA-30) perfectly complementary to mature
miR-24 was inserted into pGL3-CM, in which the multiple
cloning site of the pGL3-control vector (Promega,
Madison, WI, USA) was removed and placed downstream
of the luciferase gene as described (29,38), to generate
miR-24 ‘sensor’.
Cellculture andluciferase reporter assay
Primary myoblast cells were obtained from the gastro-
cnemius muscles of Smad3
–/– mice (36) and their wild-type
littermates as described (39). The cells were propagated
on culture plates coated with collagen (Sigma-Aldrich,
St Louis, MO, USA) in growth medium (GM). C2C12
myoblast cells were cultured as described (40). To induce
myogenesis in vitro, the proliferating myoblasts were
shifted from GM into diﬀerentiation medium (DM)
and harvested at the indicated times. rhTGF-b1 (R&D
Systems, Inc., Minneapolis, MN, USA) was added into
DM at the ﬁnal concentration of 5ng/ml to inhibit
myogenesis if needed. GM for isolated primary myoblasts
consists of DMEM supplemented with 15% fetal bovine
serum (GIBCO BRL, USA), 1% glutamine and penicillin-
streptomycin (HyClone, USA), and 2.5ng/ml of bFGF
(R&D Systems, Inc., Minneapolis, MN, USA). GM for
C2C12 consists of DMEM supplemented with 10%
newborn calf serum (GIBCO BRL, USA), 1% glutamine
and penicillin-streptomycin. DM for both C2C12 and
primary myoblasts consists of DMEM supplemented with
2% horse serum (HyClone, USA), 1% glutamine and
penicillin-streptomycin.
For luciferase assay, reporter plasmids were
co-transfected with phRG-TK vectors (Promega,
Madison, WI, USA), which express synthetic renilla lucif-
erase to normalize transfection eﬃciency, using lipofecta-
mine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
Luciferase activities were detected with Dural-luciferase
reporter assay reagents (Promega, Madison, WI, USA)
using LB 960 Centro XS3 luminometer (Berthold
Technologies, GmbH & Co. KG, Germany).
Chromatin Immunoprecipitation Assay (ChIP)
ChIP was performed according to the recommendation of
Chromatin Immunoprecipitation Assay Kit of Upstate
Biotechnology, Charlottesiville, VA. Antibodies used for
ChiP were all purchased from Santa Cruz Biotechnology.
The genomic region of miR-24-2 ﬂanking the potential
Smads-binding site was ampliﬁed with the following
primer paires: 50-AGTAGAGGAGGGCTAGGGTGTG
GA-30,5 0-TCTTGCTTGCCTGCCTATCTTGAC-30.
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To express miR-24 in C2C12 cells, retroviral vector
pINCO-miR24 was transfected into PLAT-E cells with
FuGene6 (Roche Ltd, Switzerland) to be packaged. Two
days later, the cell culture medium was collected and
ﬁltered with 0.45mm ﬁlter (Pall Corporation, East Hills,
NY, USA) to get virus-containing medium. The medium
was mixed with fresh cultural medium of equal volume
containing 8mg/ml polybrene (Sigma-Aldrich, St Louis,
MO, USA), and then used to infect C2C12 cells. 24h later,
the cells were transferred to DM to induce myogenesis for
indicated times, or used for electroporation.
To inhibit the function of miR-24,2 0-O-methyl
antisense inhibitory oligoribonucleotides targeted
towards miR-24 (50-CUGUUCCUGCUGAACUGA
GCCA-30) and scrambled sequence (50-CCUUCGAC
UUCGCGUGAUCAGA-30) were purchased from
GeneChem (GeneChem Co., Ltd, Shanghai, China) and
introduced into C2C12 cells by electroporation with Gene
Pulser (Bio-rad Lab., Hercules, CA, USA) (50nM/each
reaction)
Northern blot
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) based on the suggested protocol.
RNA quality was assessed by 1% agarose gel electro-
phoresis in the presence of ethidium bromide. Northern
blot analysis was performed as described (41) using 20mg
total RNA from each sample. Probes were synthesized in
Invitrogen Biotechnology Co., Ltd (Beijing) as following:
miR-24 (MI0000572), 50-CTGTTCCTGCTGAACTGA
GCCA-30; miR-23a (MI0000571), 50-GGAAATCCCTG
GCAATGTGAT-30; miR-27a (MI0000578), 50-GCGGA
ACTTAGCCACTGTGAA-30. Probes were labeled with
32P g-ATP using T4 polynucleotide kinase (New England
Biolabs, Inc., Ipswich, MA, USA).
Semi-quantitative and real-time RT-PCR
Reverse transcription PCR was performed essentially as
described (42) using the mRNA selective PCR kit
(DRR025A, TaKaRa, Dalian, China). Brieﬂy, 2mg total
RNA was reversely transcribed by AMV reverse tran-
scriptase XL with Oligo dT primer. Primer pairs used were
listed as following: MEF2d (NM_133655), 50-CAT
CAGCATCAAGTCAGAACC-30 and 50-GAGGGAG
TGGGAACCATC-30; Myf5 (NM_008656), 50-AAG
AACAGCAGCTTTGAC and A-30,5 0-CGTGATAGA
TAAGTCTGGAGC-30; MyoD (NM_010866), 50-GCTA
CGACACCGCCTACTACA-30 and 50-GGGTCTGGG
TTCCCTGTTC-30; Myogenin (NM_031189), 50-TGAA
TGCAACTCCCACAGC-30 and 50-CACCCAGCCTG
ACAGACAA-30; MHC (NM_010855), 50-CTTGGT
GGACAAACTACAGACT-30 and 50-TGCAGAATT
TATTTCCGTGAT-30; b-actin (NM_007393), 50-CTGG
CTGGCCGGGACCTGAC-30 and 50-CCGCTCGTTGC
CAATAGTGATGAC-30.
Real-time PCR was performed using the LightCycler
system (Roche Ltd, Switzerland) with the FastStart DNA
Master SYBR Green. The standard curve method of
quantiﬁcation was used to calculate the expression of
target genes relative to the housekeeping gene b-actin.
The control expression level was set to 1 as described
(43). Experiments were repeated at least three times.
The following primers were used: MEF2d (NM_133655),
50-CGGGGACCGGGATGATGGAC-30 and 50-GA
GCGGGAGGAGCCCAGGATAA-30; Myogenin (NM_
031189), 50-AGCGGCTGCCTAAAGTGGAGAT-30
and 50-AGGAGGCGCTGTGGGAGTTG-30; MHC
(NM_010855), 50-CGCCCACCTGGAGCGGATGA-30
and 50-CTTGCGGTCCTCCTCGGTCTGGT-30; b-actin
(NM_007393), 50-CTGGCTGGCCGGGACCTGAC-30
and 50-ACCGCTCGTTGCCAATAGTGATGAC-30.
Immunoblotting and immunostaining
Immunoblotting were carried out mainly as described
(44) using antibodies against Smad4 (provided by Dr
Ye-Guang Chen), Smad2/3 (#3102, Cell Signal Technol-
ogy, Inc.), eIF5 (sc-282, Santa Cruz Biotechnology, Inc.),
MEF2 (sc-313, Santa Cruz Biotechnology), Myogenin
(QC1653, Yuanpinghao Biotechnology, Beijing, China),
caveolin3 (ab2912, Abcam plc, Cambridge, UK) and
a-actin (BM0001, Boster Biological Technology, Wuhan,
China). Immunostaining was carried out mainly as
described (45). Brieﬂy, C2C12 cells were ﬁxed with 4%
formaldehyde for 30min at 48C and then treated with
0.5% Triton-X 100 in PBS for 5min at room temperature.
After that, cells were incubated with primary antibody
against skeletal Myosin (fast) (BM0096, Boster Biological
Technology, Wuhan, China) at 48C overnight at the
concentration of 1:100 dilutions, followed by incubation
with TRITC-conjugated secondary antibody (1:100,
Zhongshan, Beijing, China). The slides were stained with
40,6 0-diamidino-2-phenylindole (DAPI) to visualize the
nuclei. Photo capture was performed using a Nikon laser
microscope (Eclipse E600, Nikon Instruments Inc.,
Japan). The ﬂuorescence densities were measured with
Image-Pro plus 5.0 (Media Cybernetics, Inc., USA)
referring to (29). For each sample, more than eight ﬁelds
covering the whole slide were picked and red ﬂuorescence-
positive cells and total cells with DAPI staining were
counted.
Statistical analysis ofdata
All values are reported as means SD. Diﬀerences were
assessed by two-tailed Student t test using Excel software.
P<0.05 was considered to be statistically signiﬁcant.
RESULTS AND DISCUSSIONS
miR-24 isupregulated in differentiated myoblastsand
downregulated by TGF-b
To identify miRNAs regulated by TGF-b, we performed
microarray analyses of heart tissues in which Smad4 had
been speciﬁcally knocked out (35) (See ‘Materials and
methods’ section; Smad4
–/– hereafter) and heart tissues of
wild-type littermates, using a microarray that represented
347 diﬀerent miRNAs and 814 predicted miRNAs (data
not show). miR-24 was found to be upregulated in
2692 Nucleic Acids Research, 2008, Vol. 36, No. 8Smad4
–/– mouse heart tissues, compared with littermates,
and was conﬁrmed by Northern blot (Figure 1A). miR-24
was therefore considered a candidate miRNA regulated by
TGF-b. miR-24 was detected ubiquitously with relatively
high levels of expression in the heart and muscle of
2-month old mice (Figure 1B), suggesting a role for
miR-24 in the development and functional maintenance of
these tissues.
To investigate the potential involvement of miR-24 in
myogenesis, we examined miR-24 expression during the
induced diﬀerentiation of C2C12 myoblast cells.
We found that miR-24 was upregulated in diﬀerentiated
C2C12 myoblast cells as compared with undiﬀerentiated
cells (Figure 1C). The expression level of miR-24 was
closely associated with diﬀerentiation status as demon-
strated by the expression of diﬀerentiation-speciﬁc
myogenic genes such as myosin heavy chain (MHC)
(Figure 1C). Since TGF-b1 has been reported to inhibit
the induced diﬀerentiation of C2C12 myoblast cells, we
next examined the consequences of TGF-b1o nmiR-24
expression in diﬀerentiating C2C12 cells. The expression
of miR-24 was found to be dramatically reduced upon
TGF-b1 treatment (Figure 1D), while myotube formation
and expression of myogenic genes were likewise inhibited
(Figure 1E). Taken together, we propose that miR-24
is a TGF-b-regulated miRNA involved in regulation of
skeletal muscle diﬀerentiation.
TGF-bregulates expression of miR-24 atthe
transcriptional level
The expression of muscle miRNAs has been shown to be
regulated at transcriptional and/or post-transcriptional
levels (46). However, we did not detect an increase in levels
of the miR-24 pre-transcript upon treatment with TGF-b1
(Figure 1D). We propose that miR-24 regulation therefore
occurs at the transcriptional level. To test this hypothesis,
we used the promoter region 1040-bp upstream of the
transcriptional start site of miR-24-2 (47) to drive the
expression of a luciferase reporter gene in C2C12 cells.
The activity of this promoter increased with induced
diﬀerentiation of C2C12 (Figure 2A), suggesting that this
promoter region recapitulated expression of the miR-24
gene. Treatment with TGF-b1 inhibited promoter activity
(Figure 2B), supporting the proposal that TGF-b1
regulates transcription of miR-24. Since miR-23a and
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Figure 1. Suppressed expression of miR-24 by TGF-b1. (A) The expression of miR-24 in Smad4
+/+ and Smad4
–/– mouse heart tissues was detected
by Northern blot. The expression of Smad4 was detected by Western blot. U6 RNAs detected by Northern blot and eIF5 were used as loading
controls respectively. (B) Expression proﬁle of miR-24 in 2-month old mouse tissues detected by Northern blot. (C) Northern blot analysis of miR-24
expression using total RNA isolated from C2C12 myoblasts cultured in growth medium (GM) or diﬀerentiation medium (DM) for 0, 1, 3 and 5 days.
RT-PCR analysis of MHC expression to monitor the diﬀerentiation status at indicated times. (D) Northern blot analysis of miR-24 expression in
C2C12 cells transferred to DM with or without TGF-b1 (5ng/ml) for 3 days. (E) Morphological demonstration and diﬀerentiation marker expression
(MEF2d, Myf5, MyoD, Myogenin, MHC) of C2C12 cells transferred to DM with or without TGF-b1 (5ng/ml) for 3 days.
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of mouse chromosome 8 (Figure 2C), they should share
a similar regulation mechanism, which was supported by
their similar expression patterns (Figure 2D). We further
examined the eﬀects of TGF-b1 on the expression of
miR-23a and miR-27a, and found that TGF-b1 also
inhibited expression of miR-23a and miR-27a without an
elevation of their pre-transcripts (Figure 2E). These data
suggest that TGF-b inhibits the expression of miR-24 at
the transcriptional but not post-transcriptional level.
Smad3isrequired forthe inhibition of miR-24 expression
byTGF-b
Smad3 is central in transducing TGF-b signaling during
myogenesis (19,20). Therefore, we hypothesized that
inhibition of miR-24 by TGF-b is also mediated by
Smad3. To test this hypothesis, we compared expression
of miR-24 in primary myoblast cells isolated from Smad3
complete knockout (Smad3
–/–) mice (36) and non-mutant
littermates. Smad3 was only detected in wild-type but not
in Smad3
–/– myoblasts (Figure 3A). Expression of miR-24
in Smad3
–/– myoblasts cultured in both growth and
diﬀerentiation media increased signiﬁcantly (Figure 3B).
This was concomitant with increased expression of
diﬀerentiation-speciﬁc myogenic genes such as MEF2d,
Myogenin, and MHC (Figure 3C) and enhanced myotube
formation (data not shown). Notably, TGF-b1 could
inhibit the expression of miR-24 (Figure 3D) along with
myogenic genes, MEF2d, Myogenin and MHC, in wild-
type primary myoblasts (Figure 3E), but failed to do so
in Smad3
–/– primary myoblasts. These data suggest a
requirement for Smad3 in the inhibition of miR-24
expression by TGF-b.
A Smads-binding site inmiR-24 promoter is essential for
the inhibition of miR-24expression by TGF-b1
In silico analysis (rVista, http://rvista.dcode.org/) indi-
cated that a potential Smads-binding site (GTGGAT
CAGCAAGCT) was found between ( 241) ( 255) bp
in the miR-24-2 promoter region, and the site is evolution-
ally conserved. This suggested us that the site might be
the TGF-b responding element through Smads in the miR-
24-2 promoter region. To prove this, a ChIP assay was
performed to examine the interaction of Smads proteins
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Figure 2. TGF-b1 inhibits the transcription of miR-24 and clustered genes. (A) C2C12 cells transfected with reporter vector containing miR-24
promoter were ﬁrst cultured in GM for 24h, and then transferred into DM for 1 and 3 days, the luciferase activities were monitored at indicated time
points with pGL-3 basic vector as a negative control. The results were shown as the relative expression of ﬁreﬂy luciferase against renila luciferase.
One star means P<0.05, two stars mean P<0.01. (B) C2C12 cells transfected with reporter vector containing miR-24 promoter were transferred into
DM with or without TGF-b1 (5ng/ml) for 1.5 days, the luciferase activities were monitored with pGL-3 basic and control vector as negative controls
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in DM cultured cells. One star means P<0.05, two stars mean P<0.01. (C) Schematic structures of the miR-24 cluster in mouse Chromosome 8.
(D) Expression proﬁle of miR-23a and miR-27a in 2-month old mouse tissues detected by Northern blot. (E) Northern blot analysis of the expression
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Both antibodies against Smad3 and Smad4 could success-
fully immunoprecipitate the DNA fragment containing the
potential Smads-binding site (Figure 4B), supporting that
both Smad3 and Smad4 could physically interact with this
miR-24-2 promoter region. Furthermore, we examined the
eﬀects of TGF-b1 on the activity of miR-24-2 promoter
with a mutated Smads-binding site (Figure 4A). As shown
in Figure 4C and D, TGF-b1 failed to inhibit the
transcription of miR-24-2 promoter carrying a mutated
Smads-binding site in both NIH-3T3 and C2C12 cells.
These results suggest that this Smads-binding site is
essential for TGF-b1-induced inhibition of miR-24
expression.
TGF-b-regulated miR-24 promotes myoblast differentiation
To address the role of miR-24 during myogenesis, we
transfected C2C12 myoblasts with 20-O-methyl antisense
inhibitory oligoribonucleotides, which have been shown
to inhibit the function of miRNAs (48,49). Treatment
with miR-24 antisense oligoribonucleotides dramatically
inhibited C2C12 myoblast diﬀerentiation, as indicated
by reduced myotube formation (Figure 5A and B). The
reduced expression of miR-24 was conﬁrmed by Northern
blot (Figure 5C). A decrease in both early and late
myogenic markers, Myogenin and MHC, as well as
MEF2, a-actin and caveolin3 upon the treatment of miR-
24 antisense oligoribonucleotides was also detected by real-
time PCR (Figure 5D) and Western blot (Figure 5E).
Synthetic control oligoribonucleotides did not signiﬁcantly
aﬀect diﬀerentiation (Figure 5A–E). Furthermore, we
overexpressed miR-24 using the retroviral vector pINCO
(Figure 6A) (37) in C2C12 cells treated with miR-24
antisense oligoribonucleotides, and found that overexpres-
sion of miR-24 almost restored the expression of myogenic
markers (Figure 5F–H). All these results suggested that
miR-24 is a promoting factor of myogenesis.
In order to further prove the involvement of miR-24 in
TGF-b-regulated myogenesis, we overexpressed miR-24 in
C2C12 cells (Figure 6A) (37) and treated them with TGF-
b1. Expression of miR-24 was examined by Northern blot
analysis (Figure 6B). The activity of miR-24 was validated
using a miR-24 ‘sensor’ (38), in which the complementary
sequence was cloned downstream of the luciferase gene
(Figure 6C). C2C12 cells overexpressing miR-24 showed
accelerated myotube formation and increased expression
of myogenic marker MHC, and this was inhibited by
addition of TGF-b1 (Figure 6D and E). RT-PCR and
Western blot analyses conﬁrmed that overexpression of
miR-24 in C2C12 resulted in upregulation of muscle
transcriptional factors MEF2d and Myogenin, and myo-
blast diﬀerentiation markers MHC and a-actin, which was
suppressed by treatment with TGF-b1 (Figure 6F and G).
Transfection of the pINCO vector did not aﬀect expres-
sion of these genes (Figure 6F and G). In addition, we
found that overexpressed miR-24 was also able to partially
restore expression of muscle transcriptional factors and
myogenic markers normally inhibited by TGF-b
(Figure 6F and G). These data demonstrate that miR-24
is a downstream target of TGF-b, and suppressed
expression of miR-24 may constitute a mechanism by
which TGF-b inhibits myogenesis.
Taken together, we have discovered a new mechanism
for the inhibition of myogenesis by TGF-b that involves the
suppression of a non-muscle-speciﬁc miRNA. We found
that miR-24 was upregulated in diﬀerentiated myoblasts
andcouldbeinhibitedbyTGF-b atthetranscriptionallevel
(Figures 1A, D and 2B). Moreover, Smad3 ablation
completely blocked inhibition of miR-24 expression by
TGF-b (Figure 3D). Furthermore, ectopic expression of
miR-24 enhanced diﬀerentiation of C2C12 myoblasts,
and partially rescued inhibited myogenesis by TGF-b
(Figure 6). Thus, we have shown that miR-24 is an essential
miRNA for the modulation of TGF-b-inhibited myogen-
esis. Since changed expression of miR-24 aﬀects both early
and late myogenic markers, the underlying mechanism
might be that miR-24 regulates an unknown upstream
signal which then aﬀects the expression of both early and
late myogenic markers. It’s also possible that miR-24 ﬁrst
regulates the expression of early genes (myogenin and
MEF2), which then aﬀects the expression of late genes
(MHC, a-actin and caveolin3 et al.). More experiments are
needed to address the detailed mechanisms.
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Nucleic Acids Research, 2008, Vol. 36, No. 8 2695We also noticed that miR-24 clustered closely with
miR-23, miR-27 and miR-189 at two genomic loci. miR-
24-2, miR-23a and miR-27a cluster in a narrow intergenic
region of  400bp on Chromosome 8 (Figure 2C), while
miR-24-1, miR189, miR-23b and miR27b are located in an
intronic region of <800bp on chromosome 13. Moreover,
miR-24-1 and miR-189 are generated from a common pre-
transcript. We showed that miR-23a and miR-27a shared
expression patterns with miR-24 and were also inhibited by
TGF-b (Figures 1B, 2D and E), suggesting that the
miRNAs in the miR-24 cluster might cooperatively regulate
TGF-b-mediated inhibition of myogenesis. This proposal is
consistent with the opinion that polycistronic miRNAs
regulate common molecular events cooperatively
(28,50,51). Recent studies revealed that clustered miR-1
and miR-133 have distinct functions in regulating skeletal
muscle proliferation and diﬀerentiation (29). Whether the
miRNAs in the miR-24 cluster play diﬀerent roles in
modulating myoblast proliferation and diﬀerentiation in
response to TGF-b signaling needs to be further clariﬁed.
Current data on the roles of miRNAs in myogenesis has
been obtained largely from studies on muscle-speciﬁc
miR-1, miR133 and miR-206 (29,52,53). However, the
roles of non-muscle-speciﬁc miRNAs in myogenesis have
not been thoroughly examined. A recent study showed
that the non-muscle-speciﬁc miRNA, miR-181 is involved
in the establishment of myoblast diﬀerentiation (33). Here,
we identiﬁed miR-24 as another non-muscle-speciﬁc
miRNA involved in myogenesis. In addition to being
strongly induced during myogenesis (Figure 1C), miR-24
expression is maintained at high levels in terminally
diﬀerentiated muscle tissues including heart and skeletal
muscle (Figure 1B). These observations suggest that
miR-24 might function during both diﬀerentiation and
homeostatic maintenance of cardiac and skeletal muscle
tissues. Indeed, previous studies have shown that miR-24
is upregulated during cardiac hypertrophy and is able
to induce hypertrophic growth when overexpressed
in primary cardiomyocytes (54). Considering that
miR-24 is broadly expressed in multiple tissues
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2696 Nucleic Acids Research, 2008, Vol. 36, No. 8(Figure 1C), we speculate that miR-24 might play diﬀerent
roles in the homeostasis of these tissues. Analysis of a
tissue-speciﬁc knockout of miR-24 will help to address this
issue.
In conclusion, we demonstrated that miR-24, and
possibly its clustered miRNAs, is required for the
modulation of TGF-b-inhibited myoblast diﬀerentiation,
providing new clues for better understanding the molec-
ular mechanisms underlying the physiological roles of
TGF-b during myogenesis.
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